HomeCompareNWRV vs ABBV

NWRV vs ABBV: Dividend Comparison 2026

NWRV yields 20408.16% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NWRV wins by $64137456153342001152.00M in total portfolio value
10 years
NWRV
NWRV
● Live price
20408.16%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64137456153342001152.00M
Annual income
$63,525,134,733,775,620,000,000,000.00
Full NWRV calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NWRV vs ABBV

📍 NWRV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNWRVABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NWRV + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NWRV pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NWRV
Annual income on $10K today (after 15% tax)
$1,734,693.88/yr
After 10yr DRIP, annual income (after tax)
$53,996,364,523,709,275,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NWRV beats the other by $53,996,364,523,709,275,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NWRV + ABBV for your $10,000?

NWRV: 50%ABBV: 50%
100% ABBV50/50100% NWRV
Portfolio after 10yr
$32068728076671000576.00M
Annual income
$31,762,567,366,887,810,000,000,000.00/yr
Blended yield
99.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NWRV
No analyst data
Altman Z
-0.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NWRV buys
0
ABBV buys
0
No recent congressional trades found for NWRV or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNWRVABBV
Forward yield20408.16%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$64137456153342001152.00M$102.3K
Annual income after 10y$63,525,134,733,775,620,000,000,000.00$24,771.77
Total dividends collected$64097060870337249280.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NWRV vs ABBV ($10,000, DRIP)

YearNWRV PortfolioNWRV Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,051,516$2,040,816.33$11,550$430.00+$2.04MNWRV
2$393,481,853$391,286,730.22$13,472$627.96+$393.47MNWRV
3$70,560,268,237$70,139,242,654.99$15,906$926.08+$70560.25MNWRV
4$11,830,233,600,282$11,754,734,113,267.86$19,071$1,382.55+$11830233.58MNWRV
5$1,854,541,731,801,032$1,841,883,381,848,729.50$23,302$2,095.81+$1854541731.78MNWRV
6$271,833,874,765,240,000$269,849,515,112,212,900.00$29,150$3,237.93+$271833874765.21MNWRV
7$37,257,064,005,127,240,000$36,966,201,759,128,440,000.00$37,536$5,121.41+$37257064005127.20MNWRV
8$4,774,931,791,663,175,000,000$4,735,066,733,177,689,000,000.00$50,079$8,338.38+$4774931791663175.00MNWRV
9$572,263,008,940,552,750,000,000$567,153,831,923,473,140,000,000.00$69,753$14,065.80+$572263008940552768.00MNWRV
10$64,137,456,153,342,000,000,000,000$63,525,134,733,775,620,000,000,000.00$102,337$24,771.77+$64137456153342001152.00MNWRV

NWRV vs ABBV: Complete Analysis 2026

NWRVStock

Nationwide RV & Resorts, Inc. through its subsidiaries, engages in discovering, developing, and distributing green products and services. It intends to develop and market energy saving diode for standard light bulbs; and hydrogen assist cell for internal combustion engines. The company also operates a Glamping Resort located near Bryce Canyon in southern Utah. Nationwide RV & Resorts, Inc. was formerly known as Bakken Water Transfer Services, Inc. and changed its name to Nationwide RV & Resorts, Inc. in March 2025. The company was founded in 1989 and is headquartered in Minot, North Dakota.

Full NWRV Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NWRV vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NWRV vs SCHDNWRV vs JEPINWRV vs ONWRV vs KONWRV vs MAINNWRV vs JNJNWRV vs MRKNWRV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.